Men's Health Month: Key tips on diabetes and heart health
CONNECTICUT (WTNH) — June is Men's Health Month, and News 8 is bringing you expert advice all month long.
Men's Health Month: Tips from a Connecticut urologist
Ricky Le Pera, director of cardiac and pulmonary rehabilitation at Griffin Health and Michael Desjardins, the center for healthy living manager, came into our studio to talk about issues like diabetes and heart health.
They discussed common health beliefs like whether or not red meat is bad for you and how many vegetables you should be consuming regularly.
Watch the full interview in the player above.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the Company believes the only remaining item under FDA review is the finalization of the labelling. 'We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks,' said Ben Palleiko, CEO of KalVista. 'At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering.' About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older and are investigating its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Yahoo
an hour ago
- Yahoo
ShelbyCares event encourages community to address health needs
MEMPHIS, Tenn. — Community partners have teamed up to bring health resources to the community. The ShelbyCares Community Health Fair kicked off Friday morning, welcoming people of all ages and bringing essential health and social services to medically underserved neighborhoods. From 9 a.m. to 2 p.m., Shelby County residents were able to visit the ShelbyCares office in Southwest Memphis for the family-friendly event, which featured free activities including haircuts, painting, CPR training, screenings, and more. 'I came to gather information. I take it back to the community, people in the community, so I can share it with them, so they can enjoy some of these benefits being offered,' said Ray Hilliard. Organizers say last year's turnout was great, and they expected to see nearly 300 people visit the over 30 vendors. Friday marked the second year for the annual event. 📡 for Memphis and the Mid-South. 📧 and have the latest top stories sent right to your inbox. 'We are here to take care of their needs and encourage people to come out and take ownership of their health. It doesn't matter what the administration is; what is happening across. But I feel that ownership lies with the individual, and that's what I've been encouraging them to do,' said Annie Ninan, Deputy Executive Director of Tennessee Population Health Consortium. Those in attendance encouraged others to educate themselves on the importance of taking care of their health. 'I was introduced to this by my sister. So I came to the yoga class, and from there, I came to the aerobics exercise class,' said Gloria Bibbs. Heart disease and diabetes are a couple of the top leading causes of death in Shelby County, according to data from the Shelby County health department. Those in the health care field say some diseases are largely preventable and encourage residents to be proactive rather than reactive when it comes to wellness. 'One of the things we hope we can keep our program, keep it free. And so that's one of the things we try to encourage, that it's free. It's here for the community. And we don't just do screenings once. It's once a year, once a month. If you're time to come to check their numbers,' said Belinda Gray, a certified health coach with ShelbyCares. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned -2.4%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has gained 10.1%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Hims & Hers Health is expected to post earnings of $0.17 per share, indicating a change of +183.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $0.73 points to a change of +170.4%. from the prior year. Over the last 30 days, this estimate has changed +0.6%. For the next fiscal year, the consensus earnings estimate of $1.04 indicates a change of +42.4% from what Hims & Hers Health is expected to report a year ago. Over the past month, the estimate has changed -0.6%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Hims & Hers Health. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Hims & Hers Health, the consensus sales estimate of $551.84 million for the current quarter points to a year-over-year change of +74.8%. The $2.34 billion and $2.9 billion estimates for the current and next fiscal years indicate changes of +58.5% and +23.8%, respectively. Hims & Hers Health reported revenues of $586.01 million in the last reported quarter, representing a year-over-year change of +110.7%. EPS of $0.2 for the same period compares with $0.05 a year ago. Compared to the Zacks Consensus Estimate of $538.09 million, the reported revenues represent a surprise of +8.9%. The EPS surprise was +66.67%. Over the last four quarters, Hims & Hers Health surpassed consensus EPS estimates two times. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Hims & Hers Health is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about Hims & Hers Health. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
